866-997-4948(US-Canada Toll Free)

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 125 Pages

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 21, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 7
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 24
A1M Pharma AB 24
Alloksys Life Sciences BV 24
Am-Pharma BV 24
Angion Biomedica Corp 25
Arch Biopartners Inc 25
Cellmid Ltd 26
CFM Pharma Holding BV 26
Cypralis Ltd 27
DURECT Corp 27
Evotec AG 27
Exponential Biotherapies Inc 28
G1 Therapeutics Inc 28
Kringle Pharma Inc 29
Mitotech SA 29
Quark Pharmaceuticals Inc 30
SBI Pharmaceuticals Co Ltd 30
Silver Creek Pharmaceuticals Inc 31
Spherium Biomed SL 31
STATegics Inc 31
Stealth BioTherapeutics Inc 32
Torrent Pharmaceuticals Ltd 32
Xigen SA 33
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles 34
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 34
ANG-4102 - Drug Profile 36
BB-3 - Drug Profile 37
brimapitide - Drug Profile 41
CAB-101 - Drug Profile 47
CC-4066 - Drug Profile 49
cilastatin - Drug Profile 50
Drug for Kidney Diseases - Drug Profile 51
DUR-928 - Drug Profile 52
EA-230 - Drug Profile 57
elamipretide - Drug Profile 59
G-1T100182 - Drug Profile 68
IL-233 - Drug Profile 69
iron sucrose + Sn protoporphyrin - Drug Profile 70
K-1052 - Drug Profile 71
KP-100IT - Drug Profile 72
Metablok - Drug Profile 74
MG-53 - Drug Profile 75
NOXD-21 - Drug Profile 77
NYK-1341 - Drug Profile 78
Plastomitin - Drug Profile 79
QPI-1002 - Drug Profile 80
R-190 - Drug Profile 84
Recombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug Profile 85
Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 86
Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug Profile 90
Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile 92
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 93
RLS-003 - Drug Profile 94
RMC-035 - Drug Profile 95
SGF-1 - Drug Profile 99
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 100
Small Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug Profile 101
STSE-15 - Drug Profile 102
SUL-138 - Drug Profile 104
TRC-160334 - Drug Profile 105
TTX-332 - Drug Profile 106
Vanadis-03 - Drug Profile 107
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 108
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 110
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 111
Featured News & Press Releases 111
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 121
Disclaimer 122

List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Arch Biopartners Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by CFM Pharma Holding BV, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cypralis Ltd, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *